Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells - PubMed (original) (raw)
. 1996 Aug 21;88(16):1146-51.
doi: 10.1093/jnci/88.16.1146.
Affiliations
- PMID: 8757194
- DOI: 10.1093/jnci/88.16.1146
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells
Y Takahashi et al. J Natl Cancer Inst. 1996.
Abstract
Background: Development of new blood vessels is essential for tumor growth and metastasis and depends on the production of angiogenic factors by tumor and/or infiltrating cells. We previously showed that vascular endothelial growth factor (VEGF) expression and vessel count correlate with metastasis in human colon cancer. Although most tumors with high vessel counts express high levels of VEGF, some do not. Recently, platelet-derived endothelial cell growth factor (PD-ECGF), another potent angiogenic factor, has been reported to be expressed in colon cancer.
Purpose: In this study, we examined the role of PD-ECGF in colon cancer angiogenesis and whether PD-ECGF is derived from the tumor or infiltrating cells.
Methods: Immunostaining for PD-ECGF was performed on 96 colon cancer specimens, some of which were previously stained for VEGF and factor VIII, a marker that is specific for endothelial cells. Double staining was done by using antibodies to PD-ECGF and to CD68 (macrophage specific) or CD3 (lymphocyte specific) to confirm which infiltrating cells produce PD-ECGF. Northern blot analysis for PD-ECGF messenger RNA (mRNA) was performed on four colon cancer specimens and corresponding normal colon mucosae (same patients) and four human colon cancer cell lines (KM12SM, SW620, HT29, and NCI-H508) to determine whether colon cancer epithelium expresses PD-ECGF.
Results: Immunohistochemical analysis demonstrated that PD-ECGF was expressed in infiltrating cells in most of the colon cancer specimens (80 [83%] of 96) but rarely in tumor epithelium (five [5%] of 96). Double staining demonstrated that infiltrating cells staining positive for both PD-ECGF and CD68 were more predominant than those staining positive for both PD-ECGF and CD3. The intensity of staining for PD-ECGF in infiltrating cells correlated with vessel counts (Spearman's rank correlation coefficient (R) = .29; P = .004), but did not correlate with the intensity of VEGF staining (R = .176, P = .086) or metastasis (Mann-Whitney U test, P = .253). PD-ECGF staining intensity was higher in specimens with a high vessel count (> 50 at high magnification) and low VEGF-staining intensity (< or = 2+) than in specimens with a high vessel count (again, > 50) and high VEGF-staining intensity (3+). Northern blot analysis revealed that colon cancer specimens and normal mucosae expressed relatively high levels of PD-ECGF mRNA, whereas PD-ECGF mRNA transcripts were not detectable in colon cancer cell lines.
Conclusions and implications: PD-ECGF expression in human colon cancer specimens is associated with vessel count and may be responsible for tumor vascularity in those tumors with low VEGF expression. Infiltrating cells expressing PD-ECGF may contribute to angiogenesis, thus providing an additional mechanism for tumor neovascularization.
Comment in
- What is the role of thymidine phosphorylase in tumor angiogenesis.
Folkman J. Folkman J. J Natl Cancer Inst. 1996 Aug 21;88(16):1091-2. doi: 10.1093/jnci/88.16.1091. J Natl Cancer Inst. 1996. PMID: 8757181 No abstract available.
Similar articles
- Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.
Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M, Ellis LM. Takahashi Y, et al. Clin Cancer Res. 1998 Feb;4(2):429-34. Clin Cancer Res. 1998. PMID: 9516932 - The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion.
Takahashi Y, Ellis LM, Mai M. Takahashi Y, et al. Oncol Rep. 2003 Jan-Feb;10(1):9-13. Oncol Rep. 2003. PMID: 12469136 - Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis.
Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, Tsuji S, Nakajima S, Doi R, Imamura M. Fujimoto K, et al. Eur J Cancer. 1998 Aug;34(9):1439-47. doi: 10.1016/s0959-8049(98)00069-0. Eur J Cancer. 1998. PMID: 9849429 - VEGF and colon cancer growth beyond angiogenesis: does VEGF directly mediate colon cancer growth via a non-angiogenic mechanism?
Ahluwalia A, Jones MK, Matysiak-Budnik T, Tarnawski AS. Ahluwalia A, et al. Curr Pharm Des. 2014;20(7):1041-4. doi: 10.2174/1381612819999131218175905. Curr Pharm Des. 2014. PMID: 23755727 Review. - Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy.
Griffiths L, Stratford IJ. Griffiths L, et al. Br J Cancer. 1997;76(6):689-93. doi: 10.1038/bjc.1997.447. Br J Cancer. 1997. PMID: 9310231 Free PMC article. Review.
Cited by
- Transient expression of anti-VEFGR2 nanobody in Nicotiana tabacum and N. benthamiana.
Modarresi M, Javaran MJ, Shams-Bakhsh M, Zeinali S, Behdani M, Mirzaee M. Modarresi M, et al. 3 Biotech. 2018 Dec;8(12):484. doi: 10.1007/s13205-018-1500-z. Epub 2018 Nov 15. 3 Biotech. 2018. PMID: 30467531 Free PMC article. - Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells.
Iwai T, Harada Y, Saeki H, Oki E, Maehara Y, Yonemitsu Y. Iwai T, et al. Oncotarget. 2018 Apr 3;9(25):17620-17630. doi: 10.18632/oncotarget.24811. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707135 Free PMC article. - Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy.
Raica M, Cimpean AM. Raica M, et al. Pharmaceuticals (Basel). 2010 Mar 11;3(3):572-599. doi: 10.3390/ph3030572. Pharmaceuticals (Basel). 2010. PMID: 27713269 Free PMC article. Review. - Current targeted therapies in the treatment of advanced colorectal cancer: a review.
Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Moriarity A, et al. Ther Adv Med Oncol. 2016 Jul;8(4):276-93. doi: 10.1177/1758834016646734. Epub 2016 May 29. Ther Adv Med Oncol. 2016. PMID: 27482287 Free PMC article. Review. - Clinicopathological significance of vascular endothelial growth factor, thymidine phosphorylase and microvessel density in colorectal cancer.
Kimura Y, Morohashi S, Yoshizawa T, Suzuki T, Morohashi H, Sakamoto Y, Koyama M, Murata A, Kijima H, Hakamada K. Kimura Y, et al. Mol Med Rep. 2016 Feb;13(2):1551-7. doi: 10.3892/mmr.2015.4687. Epub 2015 Dec 17. Mol Med Rep. 2016. PMID: 26676225 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources